Morning Overview on MSN
A bispecific antibody beat a standard immunotherapy regimen head-to-head in squamous lung cancer at ASCO 2026
A bispecific antibody that simultaneously targets PD-1 and VEGF extended overall survival by more than four months compared ...
SurvivorNet on MSN
A new type of immunotherapy drug showed striking results in hard-to-treat lung cancer, but more data is needed for US patients
A large clinical trial in China (HARMONi-6) found that a new immunotherapy drug, ivonescimab, may help patients with advanced ...
A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.
Despite recent advances in immunotherapy and targeted therapy, most patients with non-small-cell lung cancer (NSCLC) continue to have disease progression and develop resistance to current treatments.
MedPage Today on MSN
Ultra-Low-Dose Immunotherapy May Benefit Cancer Patients in Low-Resource Countries
Regimen showed benefit in advanced head and neck cancer ...
Comparison of postoperative adjuvant therapy and surgery alone in pathological N1-2 esophageal squamous cell carcinoma: A prospective multi-center randomized controlled trial. This is an ASCO Meeting ...
Read more about ASCO results showing improved survival with TMC-I in recurrent or metastatic head and neck cancer.
Skin malignancies are the most common cancers in the United States. 1 Typically, skin cancer is categorized as either melanoma or nonmelanoma skin cancer, which is also known as keratinocyte ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results